Nakamura Tatsuya, Takahashi Hakuo
Department of Clinical Sciences and Laboratory Medicine, Kansai Medical University, Hirakata Hospital, 2-3-1 Shinmachi, Hirakata, Osaka, 572-1191, Japan.
J Infect Chemother. 2006 Jun;12(3):132-8. doi: 10.1007/s10156-006-0438-y.
The purpose of this study was to evaluate the susceptibility to antifungal agents of Candida spp. isolated from blood samples from patients in our hospital, located in Osaka, Japan. We also examined the clinical background of these patients. We analyzed fungi isolated from clinical blood samples obtained in our hospital over a period of 10 years (1993 to 2002). Antifungal susceptibility testing was carried out for six agents, using the National Committee of Clinical Laboratory Standards (NCCLS) M-27-A2 method. The clinical backgrounds were reviewed using the medical records of 125 patients who were diagnosed as having candidemia. The major fungi isolated were Candida parapsilosis (39.2%) and C. albicans (30.1%), and both were sensitive to fluconazole. One strain of C. glabrata and six strains of C. krusei were resistant to fluconazole, and they constituted 4.4% of all Candida spp. isolated. With the exception of C. parapsilosis, most fungi were susceptible to micafungin, although there is no universally agreed breakpoint for this drug. Analysis of the patients' clinical backgrounds revealed that the major underlying disease was cancer (46.4% excluding hematological malignancies). C. krusei was detected almost exclusively in patients with hematological malignancies. Indwelling venous catheters had been responsible for infection in 93.6% of the infected patients. The clinical outcomes of the 125 patients were favorable in 52% and poor in 48%, and subsequent removal of the indwelling catheters was effective in about half of the patients in whom this was done, with good prognosis. To prevent mycosis and its complications, indwelling catheters should be avoided as much as possible. Attention must be paid to the possibility that resistant isolates of Candida spp. can be selected as a result of the use of antifungal agents.
本研究旨在评估从位于日本大阪的我院患者血液样本中分离出的念珠菌属对抗真菌药物的敏感性。我们还研究了这些患者的临床背景。我们分析了我院在10年期间(1993年至2002年)从临床血液样本中分离出的真菌。使用美国国家临床实验室标准委员会(NCCLS)M-27-A2方法对六种药物进行了抗真菌药敏试验。通过125例被诊断为念珠菌血症患者的病历回顾其临床背景。分离出的主要真菌为近平滑念珠菌(39.2%)和白念珠菌(30.1%),二者均对氟康唑敏感。1株光滑念珠菌和6株克柔念珠菌对氟康唑耐药,它们占所有分离出的念珠菌属的4.4%。除近平滑念珠菌外,大多数真菌对米卡芬净敏感,尽管该药物尚无普遍认可的折点。对患者临床背景的分析显示,主要基础疾病为癌症(不包括血液系统恶性肿瘤时为46.4%)。克柔念珠菌几乎仅在血液系统恶性肿瘤患者中检出。93.6%的感染患者感染由留置静脉导管引起。125例患者的临床结局中,52%良好,48%不佳,对约一半进行了留置导管拔除术的患者有效,预后良好。为预防真菌病及其并发症,应尽可能避免使用留置导管。必须注意使用抗真菌药物可能导致念珠菌属耐药菌株的产生。